In vitro induction of carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes by dendritic cells transduced with recombinant adenoviruses.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Vaccine

• Publication date

  2003-12-12

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S0264-410X(03)00569-3PMID 14615150
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prolonged Maturation and Enhanced Transduction of Dendritic Cells Migrated from Human Skin Explants After In Situ Delivery of CD40-Targeted Adenoviral Vectors1

  2002cited by this paper
• Carcinoembryonic antigen as a target for therapeutic anticancer vaccines: a review.

  2002cited by this paper
• Helper-Dependent Adenoviral Vectors Efficiently Express Transgenes in Human Dendritic Cells but Still Stimulate Antiviral Immune Responses 1

  2002cited by this paper
• Carcinoembryonic antigen (CEA) presentation and specific T cell-priming by human dendritic cells transfected with CEA-mRNA.

  2002cited by this paper
• Helper-Dependent Adenoviral Vectors Efficiently Express Transgenes in Human Dendritic Cells but Still Stimulate Antiviral Immune Responses1

  2002cited by this paper
• Construction and Characterization of Adenovirus Serotype 5 Packaged by Serotype 3 Hexon

  2002cited by this paper
• Induction of Tumor-Specific Cytotoxic T Lymphocytes in Cancer Patients by Autologous Tumor RNA-Transfected Dendritic Cells

  2002cited by this paper
• Adenovirus infection enhances dendritic cell immunostimulatory properties and induces natural killer and T-cell-mediated tumor protection.

  2002cited by this paper
• Adenovirally Transduced Dendritic Cells Induce Bispecific Cytotoxic T Lymphocyte Responses Against Adenovirus and Cytomegalovirus pp65 or Against Adenovirus and Epstein-Barr Virus EBNA3C Protein: A Novel Approach for Immunotherapy

  2002cited by this paper
• Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells.

  2001cited by this paper
• Novel centrifugal method for simple and highly efficient adenovirus-mediated green fluorescence protein gene transduction into human monocyte-derived dendritic cells.

  2001cited by this paper
• Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy

  2001cited by this paper
• Cross-Presentation by Dendritic Cells of Tumor Antigen Expressed in Apoptotic Recombinant Canarypox Virus-Infected Dendritic Cells1

  2001cited by this paper
• The infection of human dendritic cells with recombinant avipox vectors expressing a costimulatory molecule transgene (CD80) to enhance the activation of antigen-specific cytolytic T cells.

  2001cited by this paper
• Specific cytolytic T-cell responses to human CEA from patients immunized with recombinant avipox-CEA vaccine.

  2000cited by this paper
• Murine dendritic cells infected with adenovirus vectors show signs of activation

  2000cited by this paper
• Immunology and immunotherapy of human cancer: present concepts and clinical developments.

  2000cited by this paper
• Immunomodulation therapy in colorectal carcinoma.

  2000cited by this paper
• Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells.

  2000cited by this paper
• In Vitro Priming with Adenovirus/gp100 Antigen-Transduced Dendritic Cells Reveals the Epitope Specificity of HLA-A*0201-Restricted CD8+ T Cells in Patients with Melanoma1

  2000cited by this paper
• Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses.

  2000cited by this paper
• Cutting Edge: CD4+ T Cell Control of CD8+ T Cell Reactivity to a Model Tumor Antigen

  2000cited by this paper
• Review: Gene-Modified Dendritic Cells for Use in Tumor Vaccines

  2000cited by this paper
• Longitudinal Follow-up of Cellular and Humoral Immunity Induced by Recombinant Adenovirus-Mediated Gene Therapy in Cancer Patients

  2000cited by this paper
• Dendritic cell based tumor vaccines.

  2000cited by this paper
• Report from the International Union Against Cancer (UICC) Tumor Biology Committee

  1999cited by this paper
• Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: comparison of intradermal versus subcutaneous administration.

  1999cited by this paper
• Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens.

  1999cited by this paper
• Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen.

  1999cited by this paper
• Recombinant adenovirus is an efficient and non‐perturbing genetic vector for human dendritic cells

  1999cited by this paper
• A triad of costimulatory molecules synergize to amplify T-cell activation.

  1999cited by this paper
• A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen.

  1999cited by this paper
• Gene transfer into human dendritic antigen-presenting cells by vaccinia virus and adenovirus vectors.

  1998cited by this paper
• Dendritic cells and the control of immunity

  1998cited by this paper
• Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells

  1998cited by this paper
• Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease.

  1998cited by this paper
• Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA

  1998cited by this paper
• Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus.

  1998cited by this paper
• Isolation of tumor-specific cytotoxic CD4+ and CD4+CD8dim+ T-cell clones infiltrating a cutaneous T-cell lymphoma.

  1998cited by this paper
• High efficiency adenovirus-mediated gene transfer to human dendritic cells.

  1998cited by this paper
• Isolation of tumor-specific cytotoxic CD4+ and CD4+CD8dim+ T-cell clones infiltrating a cutaneous T-cell lymphoma

  1998cited by this paper
• Dendritic Cells Genetically Modified with an Adenovirus Vector Encoding the cDNA for a Model Antigen Induce Protective and Therapeutic Antitumor Immunity

  1997cited by this paper
• Regression of tumors in mice vaccinated with professional antigen‐presenting cells pulsed with tumor extracts

  1997cited by this paper
• Bone Marrow–generated Dendritic Cells Pulsed with Tumor Extracts or Tumor RNA Induce Antitumor Immunity against Central Nervous System Tumors

  1997cited by this paper
• Characterization of Factors Involved in Modulating Persistence of Transgene Expression from Recombinant Adenovirus in the Mouse Lung

  1997cited by this paper
• Dendritic Cells: Unique Leukocyte Populations Which Control the Primary

  1997cited by this paper
• Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses.

  1997cited by this paper
• Dendritic cell maturation is required for initiation of the immune response

  1997cited by this paper
• Dendritic cells: unique leukocyte populations which control the primary immune response.

  1997cited by this paper
• Gene therapy with recombinant adenovirus vectors: evaluation of the host immune response.

  1997cited by this paper
• Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL.

  1997cited by this paper
• A comparison of gene transfer methods in human dendritic cells.

  1997cited by this paper
• Dendritic Cells Transduced with an Adenoviral Vector Encoding a Model Tumor-Associated Antigen for Tumor Vaccination

  1997cited by this paper
• Increased Phagocyte FcγRI Expression and Improved Fcγ-Receptor–Mediated Phagocytosis After In Vivo Recombinant Human Interferon-γ Treatment of Normal Human Subjects

  1997cited by this paper
• CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells.

  1996cited by this paper
• Endogenous presentation of a nascent antigenic epitope to CD8+ CTL is more efficient than exogenous presentation

  1996cited by this paper
• Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity

  1995cited by this paper
• Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine.

  1995cited by this paper
• CD4+ class I-restricted T cells specific for HIV gp160 315-329.

  1994cited by this paper
• Proliferating dendritic cell progenitors in human blood

  1994cited by this paper
• Vaccination with two different vaccinia recombinant viruses: long-term inhibition of secondary vaccination.

  1993cited by this paper
• MHC class‐I‐restricted auto‐tumor‐specific CD4+CD8 −T‐cell clones established from autologous mixed lymphocyte‐tumor‐cell culture (MLTC)

  1992cited by this paper
• Interactions of tumor necrosis factor with granulocyte-macrophage colony-stimulating factor and other cytokines in the regulation of dendritic cell growth in vitro from early bipotent CD34+ progenitors in human bone marrow.

  1992cited by this paper
• Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine.

  1992cited by this paper
• Overcoming inhibition of antibody responses to a malaria recombinant vaccinia virus caused by prior exposure to wild type virus.

  1991cited by this paper
• Carcinoembryonic antigen gene family: Molecular biology and clinical perspectives

  1991cited by this paper
• Construction of a defective adenovirus vector expressing the pseudorabies virus glycoprotein gp50 and its use as a live vaccine.

  1990cited by this paper
• Carcinoembryonic antigen is anchored to membranes by covalent attachment to a glycosylphosphatidylinositol moiety: identification of the ethanolamine linkage site.

  1988cited by this paper
• Delayed Cutaneous Hypersensitivity Reaction to Carcinoembryonic Antigen in Cancer Patients

  1982cited by this paper

• Recent advances in CAR T-cell engineering using synthetic biology: Paving the way for next-generation cancer treatment.

  2024cites this paper
• A Multiple-Array SPRi Biosensor as a Tool for Detection of Gynecological–Oncological Diseases

  2023cites this paper
• Breast cancer vaccines: New insights into immunomodulatory and nano-therapeutic approaches.

  2022cites this paper
• Role of Immune Cells in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma

  2021cites this paper
• Bacterial and viral vectors as vaccine delivery vehicles for breast cancer therapy.

  2020cites this paper
• An immunosensor for the determination of carcinoembryonic antigen by Surface Plasmon Resonance Imaging.

  2020cites this paper
• Adenovirus vectors in hematopoietic stem cell genome editing

  2019cites this paper
• Immunotherapy for Lewis lung carcinoma utilizing dendritic cells infected with CK19 gene recombinant adenoviral vectors

  2015cites this paper
• Adenovirus-Based Vaccines for Fighting Infectious Diseases and Cancer: Progress in the Field

  2014cites this paper
• C-JUN N-TERMINAL KINASES REGULATE ADENOVIRUS-MEDIATED AUTOPHAGY AND ANTIGEN PRESENTATION

  2013cites this paper
• Efficient Clinical Scale Gene Modification via Zinc Finger Nuclease–Targeted Disruption of the HIV Co-receptor CCR5

  2013cites this paper
• A pilot safety trial investigating a vector-based vaccine targeting carcinoembryonic antigen in combination with radiotherapy in patients with gastrointestinal malignancies metastatic to the liver

  2011cites this paper
• Generation of functional monocyte-derived fast dendritic cells suitable for clinical application in the absence of interleukin-6

  2011cites this paper
• Potential role of adoptively transferred allogeneic WT1-specific CD4+ and CD8+ T lymphocytes for the sustained remission of refractory AML

  2010cites this paper
• Drug or Vaccine?

  2010cites this paper
• Antitumor effects of murine bone marrow-derived dendritic cells infected with xenogeneic livin alpha recombinant adenoviral vectors against Lewis lung carcinoma.

  2010cites this paper
• Use of dentritic cells pulsed with HLA-A2-restricted MAGE-A1 peptide to generate cytotoxic T lymphocytes against malignant glioma

  2010cites this paper
• Efficient co-transduction of adenoviral vectors encoding carcinoembryonic antigen and survivin into dendritic cells by the CAR-TAT adaptor molecule enhance anti-tumor immunity in a murine colorectal cancer model.

  2010cites this paper
• Dendritic cell vaccine in addition to FOLFIRI regimen improve antitumor effects through the inhibition of immunosuppressive cells in murine colorectal cancer model.

  2010cites this paper
• A genetically engineered adenovirus vector targeted to CD40 mediates transduction of canine dendritic cells and promotes antigen-specific immune responses in vivo.

  2009cites this paper
• Improved therapeutic efficacy using vaccination with glioma lysate-pulsed dendritic cells combined with IP-10 in murine glioma.

  2009cites this paper
• Gene therapy as an adjuvant treatment for malignant gliomas: from bench to bedside

  2009cites this paper
• HLA-A2-restricted cytotoxic T lymphocyte epitopes from human heparanase as novel targets for broad-spectrum tumor immunotherapy.

  2008cites this paper
• Co‐administration of carcinoembryonic antigen and HIV TAT fusion protein with CpG‐oligodeoxynucleotide induces potent antitumor immunity

  2008cites this paper
• Introduction of functional chimeric E/L-selectin by RNA electroporation to target dendritic cells from blood to lymph nodes

  2008cites this paper
• Modification of CEA with both CRT and TAT PTD induces potent anti-tumor immune responses in RNA-pulsed DC vaccination.

  2008cites this paper
• Efficient antitumor immunity in a murine colorectal cancer model induced by CEA RNA‐electroporated B cells

  2008cites this paper
• H-2Kb-restricted CTL epitopes from mouse heparanase elicit an antitumor immune response in vivo.

  2008cites this paper
• Immuno-gene therapy approaches for cancer: from in vitro studies to clinical trials.

  2008cites this paper
• Streptococcal preparation OK-432 promotes the capacity of dendritic cells (DCs) to prime carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocyte responses induced with genetically modified DCs that express CEA.

  2008cites this paper
• Efficient generation of survivin-specific cytotoxic T lymphocytes from healthy persons in vitro: quantitative and qualitative effects of CD4+ T cells.

  2008cites this paper
• Benefits of gene transduction of granulocyte macrophage colony-stimulating factor in cancer vaccine using genetically modified dendritic cells.

  2007cites this paper
• Co-administration of Carcinoembryonic Antigen and Hiv Tat Fusion Protein with Cpg-oligodeoxynucleotide Induces Potent Antitumor Immunity Although Dendritic Cells (dc) Have Been Well Demonstrated as a Strong Cellular Adjuvant for a Tumor Vaccine, There Are Several Limitations for Clinical Application

  2007cites this paper
• Dendritic Cells Reconstituted with a Human Heparanase Gene Induce Potent Cytotoxic T-Cell Responses against Gastric Tumor Cells in vitro

  2007cites this paper
• Enhanced induction of anti-tumor immunity in human and mouse by dendritic cells pulsed with recombinant TAT fused human survivin protein.

  2007cites this paper
• Telomerase-pulsed dendritic cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma

  2006cites this paper
• Enhancement of anti-tumor immunity specific to murine glioma by vaccination with tumor cell lysate-pulsed dendritic cells engineered to produce interleukin-12

  2006cites this paper
• Adoptive Transfer of Epstein-Barr Virus-Specific Cytotoxic T-Lymphocytes for the Treatment of Angiocentric Lymphomas

  2006cites this paper
• Viral vaccines for cancer immunotherapy.

  2006cites this paper
• Dendritic cells transduced with recombinant adenoviruses induce more efficient anti-tumor immunity than dendritic cells pulsed with peptide.

  2006cites this paper
• In vitro anti-tumor immune response induced by dendritic cells transfected with EBV-LMP2 recombinant adenovirus.

  2006cites this paper
• In vitro anti-tumor immune response induced by dendritic cells transfected with hTERT recombinant adenovirus.

  2006cites this paper
• Transduction with a fiber-modified adenoviral vector is superior to non-viral nucleofection for expressing tumor-associated Ag mucin-1 in human DC.

  2006cites this paper
• High efficiency transduction of dendritic cells by adenoviral vectors targeted to DC-SIGN

  2005cites this paper
• Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II‐negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin‐12

  2005cites this paper
• Adenovirus as vehicle for anticancer genetic immunotherapy

  2005cites this paper
• Carcinoembryonic antigen as a target to induce anti-tumor immune responses.

  2004cites this paper
• Induction of CEA-specific Cytotoxic T Lymphocytes by Murine Dendritic Cells Expressing CEA

  2003cites this paper
• Adenovirally Transduced Dendritic Cells Induce Bispecific Cytotoxic T Lymphocyte Responses Against Adenovirus and Cytomegalovirus pp65 or Against Adenovirus and Epstein-Barr Virus EBNA3C Protein: A Novel Approach for Immunotherapy

  2002cites this paper